Endocrine implications of neurofibromatosis 1 in childhood

Carla Bizzarri, Giorgia Bottaro

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In 1882, von Recklinghausen described a group of patients with multiple tumors arising from the 'endoneurium' of peripheral nerves, and called them 'neurofibromas'. The term von Recklinghausen disease was used up to the end of the 20th century, when the gene of neurofibromatosis (NF1) was cloned on chromosome 17q11.2. The gene product is a cytoplasmic protein termed neurofibromin, regulating proliferation and maturation of both glial and neuronal progenitors during embryogenesis. Loss of neurofibromin function determines the hyperactivation of the proto-oncogene RAS, leading to an increased risk of tumor formation, predominantly affecting the skin, bone and the nervous system. NF1 is clinically and genetically distinct from neurofibromatosis type 2, characterized by bilateral vestibular schwannomas and other nervous system tumors. An increased incidence of central precocious puberty, diencephalic syndrome, GH deficiency and GH hypersecretion has been described in NF1 children. These conditions are commonly complications of optic pathway gliomas (OPG) involving the hypothalamic and sellar region. Nevertheless, these endocrine disorders have been observed also in children without evidence of OPG at magnetic resonance imaging. Clinical and laboratory follow-up is crucial in all children with NF1, particularly in those with an OPG, aiming at the early identification of signs suggestive of secondary endocrine alterations.

Original languageEnglish
Pages (from-to)232-241
Number of pages10
JournalHormone Research in Paediatrics
Volume83
Issue number4
DOIs
Publication statusPublished - May 28 2015

Fingerprint

Optic Nerve Glioma
Neurofibromatosis 1
Neurofibromin 1
Peripheral Nerves
Nervous System Neoplasms
Neurofibromatosis 2
Neurofibroma
Neurofibromatoses
Acoustic Neuroma
Proto-Oncogenes
Neuroglia
Nervous System
Genes
Embryonic Development
Neoplasms
Chromosomes
Magnetic Resonance Imaging
Bone and Bones
Skin
Incidence

Keywords

  • Gigantism
  • Glioma
  • Growth
  • Growth hormone
  • Neurofibromatosis
  • Precocious puberty

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Endocrine implications of neurofibromatosis 1 in childhood. / Bizzarri, Carla; Bottaro, Giorgia.

In: Hormone Research in Paediatrics, Vol. 83, No. 4, 28.05.2015, p. 232-241.

Research output: Contribution to journalArticle

@article{96fa93cae8ca4474a24f9d957ae1c711,
title = "Endocrine implications of neurofibromatosis 1 in childhood",
abstract = "In 1882, von Recklinghausen described a group of patients with multiple tumors arising from the 'endoneurium' of peripheral nerves, and called them 'neurofibromas'. The term von Recklinghausen disease was used up to the end of the 20th century, when the gene of neurofibromatosis (NF1) was cloned on chromosome 17q11.2. The gene product is a cytoplasmic protein termed neurofibromin, regulating proliferation and maturation of both glial and neuronal progenitors during embryogenesis. Loss of neurofibromin function determines the hyperactivation of the proto-oncogene RAS, leading to an increased risk of tumor formation, predominantly affecting the skin, bone and the nervous system. NF1 is clinically and genetically distinct from neurofibromatosis type 2, characterized by bilateral vestibular schwannomas and other nervous system tumors. An increased incidence of central precocious puberty, diencephalic syndrome, GH deficiency and GH hypersecretion has been described in NF1 children. These conditions are commonly complications of optic pathway gliomas (OPG) involving the hypothalamic and sellar region. Nevertheless, these endocrine disorders have been observed also in children without evidence of OPG at magnetic resonance imaging. Clinical and laboratory follow-up is crucial in all children with NF1, particularly in those with an OPG, aiming at the early identification of signs suggestive of secondary endocrine alterations.",
keywords = "Gigantism, Glioma, Growth, Growth hormone, Neurofibromatosis, Precocious puberty",
author = "Carla Bizzarri and Giorgia Bottaro",
year = "2015",
month = "5",
day = "28",
doi = "10.1159/000369802",
language = "English",
volume = "83",
pages = "232--241",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Endocrine implications of neurofibromatosis 1 in childhood

AU - Bizzarri, Carla

AU - Bottaro, Giorgia

PY - 2015/5/28

Y1 - 2015/5/28

N2 - In 1882, von Recklinghausen described a group of patients with multiple tumors arising from the 'endoneurium' of peripheral nerves, and called them 'neurofibromas'. The term von Recklinghausen disease was used up to the end of the 20th century, when the gene of neurofibromatosis (NF1) was cloned on chromosome 17q11.2. The gene product is a cytoplasmic protein termed neurofibromin, regulating proliferation and maturation of both glial and neuronal progenitors during embryogenesis. Loss of neurofibromin function determines the hyperactivation of the proto-oncogene RAS, leading to an increased risk of tumor formation, predominantly affecting the skin, bone and the nervous system. NF1 is clinically and genetically distinct from neurofibromatosis type 2, characterized by bilateral vestibular schwannomas and other nervous system tumors. An increased incidence of central precocious puberty, diencephalic syndrome, GH deficiency and GH hypersecretion has been described in NF1 children. These conditions are commonly complications of optic pathway gliomas (OPG) involving the hypothalamic and sellar region. Nevertheless, these endocrine disorders have been observed also in children without evidence of OPG at magnetic resonance imaging. Clinical and laboratory follow-up is crucial in all children with NF1, particularly in those with an OPG, aiming at the early identification of signs suggestive of secondary endocrine alterations.

AB - In 1882, von Recklinghausen described a group of patients with multiple tumors arising from the 'endoneurium' of peripheral nerves, and called them 'neurofibromas'. The term von Recklinghausen disease was used up to the end of the 20th century, when the gene of neurofibromatosis (NF1) was cloned on chromosome 17q11.2. The gene product is a cytoplasmic protein termed neurofibromin, regulating proliferation and maturation of both glial and neuronal progenitors during embryogenesis. Loss of neurofibromin function determines the hyperactivation of the proto-oncogene RAS, leading to an increased risk of tumor formation, predominantly affecting the skin, bone and the nervous system. NF1 is clinically and genetically distinct from neurofibromatosis type 2, characterized by bilateral vestibular schwannomas and other nervous system tumors. An increased incidence of central precocious puberty, diencephalic syndrome, GH deficiency and GH hypersecretion has been described in NF1 children. These conditions are commonly complications of optic pathway gliomas (OPG) involving the hypothalamic and sellar region. Nevertheless, these endocrine disorders have been observed also in children without evidence of OPG at magnetic resonance imaging. Clinical and laboratory follow-up is crucial in all children with NF1, particularly in those with an OPG, aiming at the early identification of signs suggestive of secondary endocrine alterations.

KW - Gigantism

KW - Glioma

KW - Growth

KW - Growth hormone

KW - Neurofibromatosis

KW - Precocious puberty

UR - http://www.scopus.com/inward/record.url?scp=84929952310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929952310&partnerID=8YFLogxK

U2 - 10.1159/000369802

DO - 10.1159/000369802

M3 - Article

VL - 83

SP - 232

EP - 241

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 4

ER -